Indonesia
Indonesia Plant
Maximizing our accumulated knowhow, we have acquired or built plants in strategic geographical locations that better enable us to address the local markets' needs.
Surabaya Plant
Daewoong Infion
Feature
- Dedicated for Biological products (EPO, EGF, Somatropin)
- Independent production lines preventing cross- contamination
- HALAL certified process management from drug substance to finished products
- Capacity: Prefilled Syringe (4M)
Area
2.484 m² (26.737 ft²)
Manufacturing
Products
Biopharmaceutical Products (EPO, EGF, hGH, BMP)
Cikarang Plant
Daewoong Biologics Indonesia (DBI)
Feature
- Dedicated as stem cell and biologics production facilities
Area
10,656m²
Manufacturing
Products
Stem cell, other Biologic and Cosmeceutical products
Construction
- Approval of the factory layout by BPOM (September 23, 2022)
- Completion of factory construction (February, 2023)
- Qualification for GMP equipment (February, 2023)
- Data collected for License application (April, 2023)
- Stem cell operational license application and inspection, license approval (2023)
GMP Approval
- Cosmetics GMP audit (October, 2023)
- Cosmetics GMP approval (’23Q4)
- Stem cell laboratory operational license from MOH (December, 2023)
Cikarang Factory's Indoor Layout
